INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2006

Oral soluble beta-1,3-D-glucan was safe, well tolerated, and increased salivary IgA at 400 mg/day in healthy volunteers

An open phase I dose-escalation study evaluated oral soluble branched yeast beta-1,3-D-glucan (SBG) given once daily for 4 consecutive days at 100 mg/day, 200 mg/day, or 400 mg/day in groups of 6 healthy non-smoking volunteers. No drug-related adverse events were observed, and repeated serum measurements revealed no systemic absorption. Saliva immunoglobulin A concentrations increased significantly at the highest dose of 400 mg/day.

Study type
Open 1:1:1 dose-escalation phase I trial
Who was studied
18 healthy non-smoking volunteers
What was measured
Safety, tolerability, systemic absorption, and salivary immunoglobulin A concentration

THE PAPER

Oral administration of a new soluble branched beta-1,3-D-glucan is well tolerated and can lead to increased salivary concentrations of immunoglobulin A in healthy volunteers.

Lehne G, Haneberg B, Gaustad P, Johansen PW, Preus H, Abrahamsen TG. Clin Exp Immunol, 2006.

PubMed 16367935 ↗DOI 10.1111/j.1365-2249.2005.02962.x ↗

Nutrients & adequacyOther health

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.